ImmuneBridge’s platform screens and manufactures high-quality allogeneic immune cells at commercial scale without sacrificing quality, in order to decrease cell therapy costs and improve their efficacy.

We have two defined goals that contribute to our mission of making affordable and accessible cell therapy cures: partner with other immune cell therapy developers and develop our internal pipeline.

Joshua Elkington from Axial podcast interviews ImmuneBridge’s Nina Horowitz, PhD